Skip to main content
Premium Trial:

Request an Annual Quote

GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana

NEW YORK — GeninCode said on Monday that it has signed an agreement to commercialize its portfolio of polygenic cardiovascular disease products in the US with commercial services provider Eversana Life Sciences.

UK-based GeninCode offers a range of tests that combine genetic and clinical data to assess individuals for CVD risk including Cardio inCode for heart attack and other CVD-related conditions, Lipid inCode for familial hypercholesterolemia, and Sudd inCode for sudden cardiac death.

Under the terms of their deal, Milwaukee-based Eversana will launch GeninCode's products, beginning with Cardio inCode, using its complete commercialization offering, which includes clinical and commercial field teams, medical science liaisons, channel management, health economics, and outcomes research and compliance.

Financial and other terms were not disclosed.

"Eversana [provides] proven launch and commercialization expertise to support our market access and will help accelerate our speed to market," GeninCode CEO Matthew Walls said in a statement.